Navigation Links
MEI Pharma's Mitochondrial Inhibitor Drug Candidate ME-344 Named One of Top 10 Oncology Products for 2012
Date:11/19/2012

E-143 and ME-344. For more information, go to www.meipharma.com.

Under U.S. law, a new drug cannot be marketed until it has been investigated in clinical trials and approved by the FDA as being safe and effective for the intended use. Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. You should be aware that our actual results could differ materially from those contained in the forward-looking statements, which are based on management's current expectations and are subject to a number of risks and uncertainties, including, but not limited to, our failure to successfully commercialize our product candidates; costs and delays in the development and/or FDA approval, or the failure to obtain such approval, of our product candidates; uncertainties or differences in interpretation in clinical trial results; our inability to maintain or enter into, and the risks resulting from our dependence upon, collaboration or contractual arrangements necessary for the development, manufacture, commercialization, marketing, sales and distribution of any products; competitive factors; our inability to protect our patents or proprietary rights and obtain necessary rights to third party patents and intellectual property to operate our business; our inability to operate our business without infringing the patents and proprietary rights of others; general economic conditions; the failure of any products to gain market acceptance; our inability to obtain any additional required financing; technological changes; government regulation; changes in industry practice; and one-time events. We do not intend to update any of these factors or to publicly announce the results of any revisions to these forward-looking statements.


'/>"/>
SOURCE MEI Pharma, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. ePharmaSolutions Launches an Innovative Patient Recruitment Application for Windows 8
2. CSL Behring Initiates Study of Subcutaneous Administration of C1-esterase Inhibitor in Patients with Hereditary Angioedema
3. Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor
4. Lilly and Incytes Oral JAK1 and JAK2 Inhibitor, Baricitinib, Showed Positive Results in Phase IIb Study in Patients with Active Rheumatoid Arthritis
5. Debiopharm and Ascepion Pharmaceuticals, Inc. Announce an Exclusive License Agreement for the Development and Commercialisation of the Dual-Targeting Kinase Inhibitor, ASP-08126 (Debio 1144), for the Treatment of Oncology Diseases
6. Emerging Markets for Enzyme Inhibitors Surge, To Grow More Than 50% by 2016
7. Global Markets for Enzyme Inhibitors
8. Global Angiogenesis Inhibitors and Stimulators Industry
9. Kinase Inhibitors Market to Reach $11.6 Billion in US, $40.3 Billion Globally by 2016
10. Grifols Initiates Safety Study of Inhaled Alpha1-Proteinase Inhibitor (Human) Following Orphan Drug Designation for Cystic Fibrosis
11. Caspase Inhibitor Enters Clinical Trial In Islet Transplantation As Treatment For Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)...   Taiho Oncology, Inc. , a subsidiary ... ), announced that the U.S. Food and ... TAS-102 (nonproprietary names: trifluridine and tipiracil hydrochloride), an ... treatment of refractory metastatic colorectal cancer (mCRC), and ... submission to the FDA. According to the American ...
(Date:10/20/2014)... 20, 2014 Norgine B.V. today ... low volume bowel preparation, NER1006, presented at the 79 ... of Gastroenterology (ACG), Philadelphia, PA , ... weight and co-primary endpoint of cleansing success. The study ... MOVIPREP ® in screening colonoscopy patients. [1] ...
(Date:10/19/2014)... Oct. 19, 2014  Henry Schein, Inc. (NASDAQ: ... care products and services to office-based dental, animal health ... in Iwase Dental Supply, Inc., a leading full-service provider ... marks Henry Schein,s entrance into Japan ... and increases to 28 the number of countries in ...
Breaking Medicine Technology:Taiho Oncology, Inc. Receives FDA Fast Track Designation for TAS-102 as a Potential Treatment for Refractory Metastatic Colorectal Cancer 2Taiho Oncology, Inc. Receives FDA Fast Track Designation for TAS-102 as a Potential Treatment for Refractory Metastatic Colorectal Cancer 3Taiho Oncology, Inc. Receives FDA Fast Track Designation for TAS-102 as a Potential Treatment for Refractory Metastatic Colorectal Cancer 4Positive Results from Phase II Data Show NER1006 Achieves High Quality Bowel Cleansing Efficacy 2Henry Schein Enters Japan With Investment in Iwase Dental Supply 2Henry Schein Enters Japan With Investment in Iwase Dental Supply 3Henry Schein Enters Japan With Investment in Iwase Dental Supply 4Henry Schein Enters Japan With Investment in Iwase Dental Supply 5
... 5 Only about a third of American women ... means they are likely missing out on potentially important ... vitamins, minerals and fiber, fruits and vegetables contain a ... support women,s health including breast and ovarian health.   ...
... Accuray Incorporated (Nasdaq: ARAY ), ... that the company was awarded a $1 million Small Business ... used toward further development of a high-energy X-ray source for ... development of a next generation, compact X-ray source with unprecedented ...
Cached Medicine Technology:Shortfalls in Carotenoid Intake May Impact Women's Health 2Shortfalls in Carotenoid Intake May Impact Women's Health 3Shortfalls in Carotenoid Intake May Impact Women's Health 4Shortfalls in Carotenoid Intake May Impact Women's Health 5Accuray Awarded $1 Million Grant by U.S. Government 2Accuray Awarded $1 Million Grant by U.S. Government 3
(Date:10/20/2014)... Pittsburgh, PA (PRWEB) October 20, 2014 ... new, minimally-invasive procedure that enables physicians to repair a ... , The MitraClip system, developed by ... regurgitation (MR), a progressive and life-threatening condition in which ... allowing blood to flow backward from the heart’s left ...
(Date:10/20/2014)... hc1.com today announced the launch of ... enables healthcare organizations of all sizes to immediately ... management (“CRM”) solution. , Designed from the ground ... healthcare industry, the hc1 Healthcare Relationship Cloud™ personalizes ... combining healthcare CRM, HIPAA-compliant collaboration, and real-time analytics ...
(Date:10/20/2014)... October 20, 2014 AttorneyOne.com, a recognized authority ... information from the FDA on Sit and Slim II ... not to purchase or use Sit and Slim II because ... II is promoted as weight loss product on various websites ... the market in 2010 for safety reasons, can significantly increase ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 National Teen Driver ... of the American Academy of Pediatrics (Ohio AAP, http://www.ohioaap.org ... in encouraging parents of teen drivers to talk to their ... road. , Motor vehicle crashes are the leading cause of ... drivers involved in fatal crashes, and 859 (42%) of those ...
(Date:10/20/2014)... Houston plastic surgeon Dr. Christopher ... of his innovative True Form Tummy Tuck® ... and faculty at The University of Texas Medical ... once a medical student. Patronella, who is a founding ... surgery practices in Texas, The Aesthetic Center for ...
Breaking Medicine News(10 mins):Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 2Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 3Health News:Healthcare Relationship Management (HRM) Leader hc1.com® Launches hc1® Quick Start™ 2Health News:FDA Advises Not to Use Sit and Slim II: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:Ohio AAP Promotes National Teen Driver Safety Week 2Health News:Plastic Surgeon Patronella Presents Artistically-Inspired Tummy Tuck Method to Future Generation of Plastic Surgeons in Texas 2
... ... ... ... BLOOMINGTON, Minn. , March 18 As part of National Colorectal Cancer Awareness Month, four health organizations have kicked off an initiative to increase screenings for Minnesotans at risk ...
... PROLOR Biotech, Inc., (OTC Bulletin Board: PBTH),  a ... it has raised $24.4 million in a private ... $0.00001 per share, to accredited investors at a ... approximate 17% discount to the average closing price of the ...
... , ... of data protection tools for VMWare platform, announced the release and availability of SnapShot Backup ... customers to use SAN snapshots and replicas for data backup and file level restore., ... (PRWEB) March 18, 2010 -- ...
... March 18, 2010 Elbit Imaging,Ltd. ("EI") (NASDAQ: ... Services, has informed EI that its "A2/Stable" rating,on a local scale, ... principal amount of up to NIS 100 million that ... in 2010. This credit rating,would also apply to additional debentures in ...
... , ... another 81,000 SF to its portfolio and plans $500,000 in improvements to the property. ... , ... 2010 -- Ensemble Healthcare Properties (an affiliate of locally based Ensemble DevMan of Arizona) in ...
... Wendei Spale, ... Cancer. ,She provides oncology patients with the comfort and relief that has not previously been ... suit their individual needs, at her wonderfully private studio, Peace of Mind Skin Care. , ... Studio City, CA (PRWEB) ...
Cached Medicine News:Health News:Minnesota Organizations Join Together to Save 500 Lives 2Health News:Minnesota Organizations Join Together to Save 500 Lives 3Health News:Minnesota Organizations Join Together to Save 500 Lives 4Health News:Minnesota Organizations Join Together to Save 500 Lives 5Health News:PROLOR Biotech Announces Sale of $24.4 Million of Common Stock 2Health News:PROLOR Biotech Announces Sale of $24.4 Million of Common Stock 3Health News:PROLOR Biotech Announces Sale of $24.4 Million of Common Stock 4Health News:SAN SnapShot Backup for VMWare - Does Your Backup Always Completes In Seconds, Is 1000x Faster and Costs 90% Less? 2Health News:SAN SnapShot Backup for VMWare - Does Your Backup Always Completes In Seconds, Is 1000x Faster and Costs 90% Less? 3Health News:Midroog Ltd., an Affiliate of Moody's Investors Services, Rates Potential new Debt of Elbit Imaging 2Health News:Midroog Ltd., an Affiliate of Moody's Investors Services, Rates Potential new Debt of Elbit Imaging 3Health News:Midroog Ltd., an Affiliate of Moody's Investors Services, Rates Potential new Debt of Elbit Imaging 4Health News:Ensemble Healthcare Properties Purchases North Valley Medical Plaza 2Health News:Ensemble Healthcare Properties Purchases North Valley Medical Plaza 3Health News:Peace of Mind Skin Care Announces new Services in Oncology Esthetics 2
... The assay is an immunometric ... measurement of Prolactin in human ... the sample is bound by ... different epitopes. One antibody is ...
... hormone secreted in significant amounts by the ... in synergy with estrogen, plays an important ... of mammary gland growth and lactation in ... effects on cell growth in other tissues ...
... The AxSYM BNP assay allows ... in the status of your heart ... BNP versus NT-ProBNP. The AxSYM BNP ... fast, simple, walk-away resultson a platform ...
... this Enzyme ImmunoAssay (EIA) is as follows: ... on a 96 well microtiter plate. After ... the trapped molecule is covalently linked to ... After washing and denaturing treatment, Angiotensin II ...
Medicine Products: